Navigation Links
Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference
Date:5/19/2011

KING OF PRUSSIA, Pa., May 19, 2011 /PRNewswire/ -- Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at an international medical congress on May 22, 2011. CSL Behring is a global biotherapeutics company specializing in plasma-derived and recombinant therapies and is a subsidiary of CSL Limited (ASX:CSL).

CSL627, a unique single-chain recombinant factor VIII (rFVIII) studied for treatment of hemophilia A, will enter phase I clinical testing.

The structure of factor VIII (FVIII) is based on two linked protein chains—a heavy one and a light one. Under certain conditions, this structure can dissociate, resulting in the formation of separated, or "dissociated," FVIII chains. CSL627 uses a strong, covalent bond that connects the light and heavy chains, thereby creating a single-chain rFVIII.

In-house studies have shown that the molecular integrity of CSL627 is significantly increased using this single-chain design, resulting in a homogenous product that may be more stable than currently available options. In addition, in-vitro studies have shown that CSL627 demonstrates a very strong affinity for von Willebrand factor (VWF) and a faster and more efficient binding to VWF than is demonstrated in wild-type FVIII. The FVIII/VWF complex plays an important role in the physiological activity and clearance of FVIII and has been shown to have an influence on the presentation of FVIII to the immune system.

"For more than 90 years, CSL Behring has been committed to providing safe and effective therapies to help improve the lives of patients and caregivers affected by hemophilia A and other rare bleeding disorders," said  Dr. Andrew Cuthbertson, Chief Scientist, CSL Limited. "Developing innovative therapeutic solutions to serious medical conditions is one important way to do that. Therefore, CSL Behring seeks to further expand its broad portfolio of products for the hemophilia community, starting with research into a single-chain rFVIII and other promising therapies."

The research leading to the initiation of the studies that CSL Behring is now conducting is the result of collaboration across the CSL Behring research sites in Marburg, Germany, in King of Prussia, PA, USA, and at facilities operated by CSL Limited in Melbourne, Australia.

CSL Behring is also at work on two recombinant fusion proteins (FP) linking coagulation factors with albumin. Both are in testing to demonstrate an extension of factor half life. One, rVIIa-FP (CSL689), is a recombinant factor VIIa albumin fusion protein for the treatment of patients with hemophilia A or B who have developed inhibitory antibodies. The other, rIX-FP (CSL654), is a recombinant fusion protein linking coagulation factor IX with albumin. It is currently recruiting for phase I studies.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema, and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.

Media Contacts:
Sheila A. Burke
Director, Worldwide Commercial Public Relations and Communications
CSL Behring
1020 First Avenue
King of Prussia, PA 19406
610-878-4209
484-919-2618 (mobile, US)
sheila.burke@cslbehring.com


'/>"/>
SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Anaphore to Present Company Overview with Focus on Atrimer Technology Platform at 13th Annual C21 BioVentures Conference
2. Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients
3. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
4. Reportlinker Adds Biomarkers: Discovery Techniques and Applications - A Global Market Overview
5. New and Updated Online Tutorials for Ensembl Legacy and Overview of Genome Browsers
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc.
7. Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
9. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on The Medical House PLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... CO (PRWEB) , ... May 03, 2016 , ... ... , announced the addition of Dr. Nancy Gillett to its Board of Directors. ... position, she served as Corporate Executive Vice President and Chief Scientific Officer. A ...
(Date:5/3/2016)... ... May 03, 2016 , ... Wearable Tech + ... conferences, will take place on June 7-8, 2016, at the New York Academy of ... incorporating technology -- including AR/VR, machine learning, apps, robotics and AI -- throughout a ...
(Date:5/3/2016)... Texas , May 3, 2016  Dr. ... plastic surgeon in The Woodlands, Texas ... destroys 24 percent of treated fat cells in just ... woman. Close to 90 percent of Americans report feeling ... options. Nonsurgical fat reduction procedures are a growing industry. ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... fertility clinics and IVF laboratories. A contingency of reproductive endocrinologists, including Dr. ... and women experiencing infertility and to help them build families. , Ovation Fertility ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):